Utility of the pooling approach as applied to whole genome association scans with high-density Affymetrix microarrays. by Schosser, A. et al.
TECHNICAL NOTE Open Access
Utility of the pooling approach as applied to
whole genome association scans with high-
density Affymetrix microarrays
Alexandra Schosser1,4*, Katrina Pirlo1, Darya Gaysina1, Sarah Cohen-Woods1, Leonard C Schalkwyk1, Amanda Elkin1,
Ania Korszun2, Cerisse Gunasinghe1, Joanna Gray1, Lisa Jones3, Emma Meaburn1, Anne E Farmer1, Ian W Craig1,
Peter McGuffin1
Abstract
Background: We report an attempt to extend the previously successful approach of combining SNP (single
nucleotide polymorphism) microarrays and DNA pooling (SNP-MaP) employing high-density microarrays. Whereas
earlier studies employed a range of Affymetrix SNP microarrays comprising from 10 K to 500 K SNPs, this most
recent investigation used the 6.0 chip which displays 906,600 SNP probes and 946,000 probes for the interrogation
of CNVs (copy number variations). The genotyping assay using the Affymetrix SNP 6.0 array is highly demanding
on sample quality due to the small feature size, low redundancy, and lack of mismatch probes.
Findings: In the first study published so far using this microarray on pooled DNA, we found that pooled cheek swab
DNA could not accurately predict real allele frequencies of the samples that comprised the pools. In contrast, the allele
frequency estimates using blood DNA pools were reasonable, although inferior compared to those obtained with
previously employed Affymetrix microarrays. However, it might be possible to improve performance by developing
improved analysis methods.
Conclusions: Despite the decreasing costs of genome-wide individual genotyping, the pooling approach may
have applications in very large-scale case-control association studies. In such cases, our study suggests that high-
quality DNA preparations and lower density platforms should be preferred.
Background
We report an attempt to extend the previously successful
approach of SNP (single nucleotide polymorphism)
microarrays and DNA pooling (SNP-MaP) [1-14].
Whereas earlier studies had employed a range of Affyme-
trix SNP microarrays interrogating between 10 K to 500
K SNPs [15], we used the Affymetrix SNP 6.0 which dis-
plays 906,600 SNP probes and 946,000 probes for the
interrogation of CNVs (copy number variations). We
have performed this genome-wide association study
(GWAS) using pooled DNA from a large depression
case-control sample (1418 cases, 1301 controls), and the
SNPs with the largest differences between cases and con-
trols were individually genotyped in the sample used to
construct the pools. In contrast to the suitability of Affy-
metrix microarrays (up to the 500 K) for successful ana-
lysis of DNA pools as established by other groups, the
properties of the Affymetrix SNP 6.0 used in the current
study were unproven at the time of investigation.
Methods
Study design
GWAS using phenotypically standardised pooled DNA
of a large depression case-control (DeCC) sample was
followed-up by individually genotyping the ‘top-hit’
SNPs. The SNP-MaP approach was conducted with the
Affymetrix Genome-Wide Human SNP Array 6.0, con-
taining approximately 1 million SNP markers [1].
Samples
Our depression case-control (DeCC) samples of 1418
patients with a diagnosis of recurrent major depression
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(MDD) and 1301 control subjects were recruited from
three clinical sites in UK (London, Cardiff and Bir-
mingham) as described previously [16]. All participants
gave written informed consent, and the study was
approved by the Local Ethical Committees of the three
centres.
DNA pooling
Blood samples were obtained from all patients and
either blood or buccal mucosa swabs obtained from
controls. Genomic DNA was extracted by an in-house
validated procedure as described previously [17,18].
Genomic DNA was quantified three times using Pico-
Green® assay (Molecular Probes, Eugene, OR, USA).
The DNA pools of the DeCC sample were created as
follows: first of all, the sample was divided into cases
and controls, and then into males and females. Subse-
quently, these groups were divided according to their
body mass index (BMI <25, BMI 25-30, BMI >30) in
the light of phenotypic analyses of DeCC, showing
strong associations between depression and various
physical diseases mediated via increased BMI [19]. We
randomly created 57 DNA-pools of on average 47.67
individuals of matched sex and phenotype (SD = 9.39),
and each individual contributed 100 ng DNA to their
pools which ranged in concentrations from 19.0 to
24.99 ng/μL.
Allelotyping the DNA pools
The Affymetrix Genome-Wide Human SNP Array 6.0 in
combination with the standard Affymetrix protocol was
used to allelotype 200 ng genomic DNA from each pool.
Water was used as a negative control to test for contami-
nation, and to test for assay performance, the manufac-
turer’s individual reference DNA was used as a positive
control. Three pools were genotyped in duplicate, serving
as technical replicates.
Generating RAS (relative allele signal) scores
In contrast to the earlier versions of Affymetrix geno-
typing arrays, the latest SNP arrays (Affymetrix Gen-
ome-Wide SNP Array 5.0 and 6.0; but not the
previously employed 500 K chip) differ in that the mis-
match probes have been discarded in favour of greater
perfect match probe density. Thus, mismatch intensi-
ties can no longer be subtracted before calculating
RAS scores, and RAS scores based on an equivalent
principle to those that have been validated for pooling
in previous work cannot, therefore, be calculated any-
more. As a consequence they may no longer represent
a good estimate of the absolute allele frequency in the
pool; however, such estimates may still be useful for
detecting frequency differences between pools [20].
Confirmatory individual genotyping
Confirmatory individual genotyping was performed
using the Sequenom MassARRAY® iPLEX Gold assay
and TaqMan® SNP genotyping platform.
Statistical analyses
Cell intensity (.CEL) files were exported and RAS scores
generated from the cell intensity data using the RAS
score algorithm as implemented in a freely available
script in R (http://sgdp.iop.kcl.ac.uk/oleo/affy), which
has now become part of an R package, the SNPMaP
package [21]. To test for significant differences between
cases and controls, an independent Student’s t-Test was
applied using R statistical software (http://www.r-pro-
ject.org/).
Results
We have performed a genome-wide association study
(GWAS) using pooled DNA of a depression case-control
sample and the Affymetrix Genome-Wide Human SNP
Array 6.0, and followed-up the ‘top-hit’ SNPs using con-
firmatory individual genotyping with Sequenom Mas-
sARRAY® iPLEX Gold or TaqMan®. Three DNA-pools
were genotyped in duplicate and hybridized to two sepa-
rate microarrays (’technical replicates’). The pairwise
correlations were 0.945, 0.965 and 0.967 respectively.
Biological replicates (pools of the same phenotypic
group) were available for the majority of pools in the
current study. We randomly selected five blood DNA
case-pools of the same phenotypic group (cases, females,
body-mass-index 25 to 30) and found an average pair-
wise correlation of 0.956; we found similar average pair-
wise correlations (0.959) for four cheek-swab-DNA
control pools of the same phenotypic group (controls,
females, body-mass-index less than 25) and four blood
DNA control-pools of the same phenotypic group
(0.967) (controls, females, body-mass-index less than
25). We allelotyped a total of 57 DNA pools of on aver-
age 47.67 individuals each (SD = 9.39), 29 pools of cases
and 28 pools of controls. All case-pools contained blood
DNA, whereas only 10 control-pools contained blood
DNA, the remainder (18) contained cheek swab DNA.
To test for significant differences in allele frequencies
between cases and controls, an independent Student’s t-
Test was applied and after excluding rare variants with
a minor allele frequency (MAF) <0.05, we found 74
SNPs crossing the genome-wide significance threshold
of 7.2 × 10-8 [22]. The top-ranked SNPs of the pooling
GWAS were followed-up by individually genotyping the
samples used to construct the pools, and the validity of
the SNP-MaP approach was assessed by comparing
allele frequency estimates from pooled DNA (RAS
scores) with individual genotyping data of 110 SNPs
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genotyped with either Sequenom MassARRAY® iPLEX
Gold (108 SNPs) or TaqMan® (2 SNPs). We performed
these analyses for cases and controls separately and,
since all case pools contained blood DNA but 18 out of
28 control pools contained cheek swab DNA, we divided
the controls into two groups according to source of
DNA. The Pearson’s correlation of the allele frequency
estimates of the DNA pools (RAS scores) and the ‘real’
allele frequencies derived from individual genotyping
was 0.9010 for the case-pools (all blood DNA) and
0.8853 for the blood DNA control-pools; however, the
correlation was only 0.2734 for the cheek swab control-
pools (see Figure 1).
Conclusions
The current study was an attempt to extend the pre-
viously successful approach of SNP microarrays and
DNA pooling (SNP-MaP) to a whole-genome associa-
tion study of MDD employing high-density microarrays.
Whereas the earlier studies had employed a range of
Affymetrix SNP microarrays comprising from 10 K to
500 K SNPs, this most recent investigation used the 6.0
chip, which displays 906,600 SNP probes and 946,000
probes for the interrogation of CNVs. The main advan-
tage of DNA pooling is that it is a way to reduce costs
in determining allele frequencies in large case/control
cohorts. Since individual genotypes cannot be deter-
mined, this process is called “allelotyping” and it enables
allele frequency differences between pools comprised
DNA from many individuals to be compared without
the need to genotype each individual.
For the purposes of allelotyping pooled DNA, there
are three subtle but potentially detrimental changes dif-
ferentiating the Affymetrix SNP 6.0 microarray from its
validated 10 K, 100 K and 500 K predecessors. First, the
feature size has decreased from 18 μm on the 10 K, to 8
μm on the 100 K, and to 5 μm on the 500 K and Affy-
metrix SNP 6.0 microarrays. Second, each SNP is inter-
rogated by 40 probes on the Affymetrix 10 K and 100
K, 24 probes for 90% of the Affymetrix 500 K, but by
only 6-8 probes on the Affymetrix SNP 6.0 microarray.
Third, the mismatch probes have been discarded from
the Affymetrix SNP 6.0 microarray, and thus mismatch
probe intensities cannot be subtracted from perfect
match probe intensities as it was the case for previous
Affymetrix microarrays up to the 500 K. To our knowl-
edge, this is the first study published so far using the
Affymetrix SNP 6.0 microarray on pooled DNA.
We created 57 DNA pools of the DeCC sample, each
containing equal amounts of DNA of on average 47.67
individuals (SD = 9.39).
We assessed validity of the genome-wide pooling
study by comparing the estimates of allele frequencies
from pooled DNA with individual genotyping data of
110 SNPs genotyped with either Sequenom MassAR-
RAY® iPLEX Gold or TaqMan®, and allele frequency
estimates provided by Affymetrix NetAffx™ (http://www.
affymetrix.com/analysis/index.affx). While there was a
high correlation (>0.99) between allele frequencies
derived from confirmatory individual genotyping and
the allele frequencies provided by Affymetrix NetAffx™,
the correlation between the allele frequency estimates
derived from the pools (RAS scores) and the ‘real’ allele
frequencies derived from individually genotyping the
samples which composed the pools was somewhat dis-
appointing. Although the correlation of RAS scores and
‘real’ allele frequencies was reasonable (but rather poor
as compared to the previous Affymetrix microarrays up
to the 500 K) for the blood DNA cases (Pearson’s corre-
lation of 0.901) and the blood DNA controls (Pearson’s
correlation of 0.885), the correlation of cheek swab
DNA controls was only 0.273. The RAS scores produced
using the Affymetrix SNP 6.0 array have a different dis-
tribution than the conventional RAS scores that had
been validated for pooling in previous work, since the
mismatch probes have been discarded in favour of
greater perfect match probe intensity. Therefore, mis-
match intensities cannot be substracted before calculat-
ing RAS scores, and the ratio of allele signal intensities
A/(A+B) is calculated instead. As a consequence, the
RAS scores derived from the Affymetrix SNP 6.0 array
are not necessarily a good estimate of the absolute allele
frequency in the pool [21]. However, this should not
affect case-control comparison in a genome-wide pool-
ing study, since we are interested in frequency differ-
ences between the groups, not necessarily in absolute
allele frequencies. Although the RAS scores indeed did
not accurately predict the ‘real’ allele frequencies in our
sample, we hypothesized that the difference between
cases and controls are expected to be the same in the
pools as in the individuals that comprise the pools. To
test this hypothesis, we calculated the ratio of the mean
allele frequencies of controls and cases (controls/cases)
for the 110 SNPs individually genotyped, and the ratio
of the mean RAS scores of control and case pools (con-
trol pools/case pools) for the same SNPs genotyped on
the Affymetrix SNP 6.0 array. Subsequently, we calcu-
lated the ratio of the two ratios, where a ratio of 1
would indicate that the mean control/case ratio of the
RAS scores for a given SNP was a perfect estimate of
the ‘real’ ratio derived from individual genotyping of the
samples composing the pools. We found that the mean
of the latter ratios was 1.01 and the standard deviation
(SD) was 0.25, with 74.55% of SNPs within one SD. Per-
forming the same analyses after separating blood and
cheek swab controls, we found a mean of 0.99 and SD
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Figure 1 Pearson’s correlation of real allele frequencies (x-axis) and frequency estimates from pooled DNA (RAS-scores, y-axis) of
BACCS controls (a) (blood DNA) and the DeCC controls (b) (cheek swab DNA) are shown. The red arrows (a) indicate, that the distribution
of RAS scores (y-axis) are now slumped towards 0.5 as a consequence of the discarded mismatch probe (thus mismatch probe intensities cannot
be substracted from perfect match probe intensities) as compared to previous Affymetrix microarrays up to the 500 K. Pooled cheek swab DNA
(b) could not sufficiently predict ‘real’ allele frequencies of the samples that comprised the pools.
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of 0.11 in case of blood controls (89.09% of SNPs within
1 SD), and a mean of 1.05 and SD of 0.39 in case of
cheek swab controls (74% of SNPs within 1 SD).
These findings suggests that the microarray allelotyp-
ing cheek swab DNA pools did not sufficiently predict
‘real’ allele frequencies of the samples comprising the
pools (see Figure 1) even though the quality of cheek
swab DNA employed was comparable to that in pre-
vious studies. The genotyping assay using the Affymetrix
SNP 6.0 array is highly demanding on sample quality
due to the small feature size, low redundancy, and lack
of mismatch probes. In contrast to the problems
encountered with cheek swab DNA, the allele frequency
estimates using blood DNA pools on the 6.0 chip were
reasonable, although inferior compared to those
obtained with previous Affymetrix microarrays up to the
500 K chip. Nevertheless, knowing the nature of the
problems encountered and the differences in the organi-
sation of the probe features distinguishing the Affyme-
trix SNP 6.0 array from its predecessors, it might be
possible, however, to improve performance by develop-
ing improved analysis methods. In addition, despite the
decreasing costs of genome-wide individual genotyping,
the pooling approach with this (and other arrays) may
still be applicable in very large-scale case-control asso-
ciation studies, preferably using high-quality blood DNA
or a less SNP dense platform as appropriate.
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